Other languages Immuneering Corporation

Equities

IMRX

US45254E1073

Market Closed - Nasdaq Other stock markets 02:00:01 04/05/2024 am IST			5-day change	1st Jan Change
1.64 ^USD	+5.13%		+11.56%	-77.69%

09/04	Immuneering Corporation Presents Preclinical Data At the American Association for Cancer Research Annual Meeting	CI
02/04	Mizuho Adjusts Price Target on Immuneering to $8 From $20 on Revised Revenue Assumptions for Lead Asset IMM-1-104, Keeps Buy Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immuneering Corporation Presents Preclinical Data At the American Association for Cancer Research Annual Meeting	09/04
Immuneering Announces First Patient Dosed in Its Phase 1/2A Trial of Imm-6-415 to Treat Advanced Solid Tumors with Raf or Ras Mutations	27/03
Sector Update: Health Care Stocks Ease Late Afternoon	16/03
Sector Update: Health Care	16/03
Immuneering Shares Decline After Analysts Downgrades, Phase 1 Cancer Therapy Data	15/03
Immuneering Announces Positive Topline Results from Phase 1 Portion of Its Phase 1/2A Clinical Trial of IMM-1-104 in Ras-Mutant Solid Tumors	14/03
Immuneering Corporation Appoints Thomas J. Schall to Its Board of Directors	12/03
Immuneering Begins Phase 2a Testing of Potential Cancer Immunotherapy; Phase 1 Data Due Out Soon	11/03
Immuneering Doses First Patient in Phase 2A Clinical Trial of IMM-1-104 in Ras-Mutant Solid Tumors	11/03
Immuneering Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	01/03
Immuneering Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	01/03
Immuneering Receives FDA's Fast Track Designation for IMM-1-104 in Pancreatic Cancer	20/02
Immuneering Corporation Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer	20/02
Immuneering Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11
Immuneering Corporation Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference	13/23/13
Immuneering Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	04/23/04
Immuneering Corporation Appoints Mallory Morales as Chief Accounting Officer, Effective July 1, 2023	15/23/15
Immuneering Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	05/23/05
Immuneering Prices $30 Million Common Stock Offering	18/23/18
Immuneering Corporation Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-Ras Program	18/23/18

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Immuneering Corporation

Equities

IMRX

US45254E1073

Other languages

Filters